Sonke Gabe S - Department of Epidemiology and Biostatistics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. g.sonke@nki.nl

基本信息

浏览量：137

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 116 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

The INFLUENCE 3.0 model: updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy

MC van Maaren, TA Hueting,DJP van Uden, M van Hezewijk,L de Munck, MAM Mureau, PA Seegers, QJM Voorham,MK Schmidt,GS Sonke, CGM Groothuis-Oudshoorn,S Siesling,

crossref（2024）

引用0浏览0引用

Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications

Simone N. Koole, Atse H. Huisman,Lonneke Timmers,Hans M. Westgeest, Edwin van Breugel,Gabe S. Sonke,Sahar Barjesteh van Waalwijk van Doorn-Khosrovani

LANCET ONCOLOGYno. 3 (2024): e126-e135

引用0浏览0WOS引用

Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer

Marleen Kok, Robbert-Jan Gielen,Sylvia Adams, Jochen K Lennerz,Priyanka Sharma,Sibylle Loibl, Erin Reardon,Gabe Sonke, Sabine Linn,Suzette Delaloge, Denis Lacombe,Tim Robinson,

Journal of clinical oncology : official journal of the American Society of Clinical Oncologypp.JCO2400372-JCO2400372, (2024)

引用0浏览0WOS引用

Gene expression profiles in clinically T1-2N0 ER+HER2− breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed

L. M. van Roozendaal,M. L. G. Vane, E. Colier,L. J. A. Strobbe,M. de Boer,G. Sonke,M. C. Van Maaren,M. L. Smidt

Breast Cancer Research and Treatmentno. 1 (2024): 103-110

引用0浏览0WOS引用

Dose selection of novel anticancer drugs: exposing the gap between selected and required doses

Catharina J P Op ‘t Hoog,Niven Mehra,Marc Maliepaard,Kalijn Bol,Hans Gelderblom,Gabe S Sonke, Adrianus J de Langen,Niels W C J van de Donk, Jeroen J W M Janssen,Monique C Minnema, Nielka P van Erp, Emmy Boerrigter

The Lancet Oncologyno. 8 (2024): e340-e351

引用0浏览0WOS引用

Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned

Milou A. Hogervorst, Christine C. van Hattem,Gabe S. Sonke,Aukje K. Mantel-Teeuwisse,Wim G. Goettsch,Lourens T. Bloem

Drug Discovery Todayno. 7 (2024): 104031-104031

引用0浏览0WOS引用

The INFLUENCE 3.0 model: time-dependent risks of locoregional recurrence and contralateral breast cancer, now also including patients treated with neoadjuvant systemic therapy

M. van Maaren, T. Hueting,D. van Uden, M. van Hezewijk,L. de Munck, A. Zeillemaker, M. Schmidt,G. Sonke, C. Groothuis-Oudshoorn,S. Siesling

European Journal of Cancer (2024): 113672

引用0浏览0引用

492 Significant reduction in stoma formation rate after introduction of HIPEC as standard practice for ovarian cancer in the Netherlands

S Lot Aronson, Alissa Belt, Willemien JVan Driel, Eleonora BLVan Dorst,Gabe S Sonke, Henk WR Schreuder

Poster and E-Posters (2024)

引用0浏览0引用

Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial

Anouk E Hiensch,Johanna Depenbusch, Martina E Schmidt,Evelyn M Monninkhof,Mireia Pelaez, Dorothea Clauss, Nadira Gunasekara,Philipp Zimmer, Jon Belloso,Mark Trevaskis,Helene Rundqvist, Joachim Wiskemann,

Nature medicine (2024)

引用0浏览0WOS引用

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

P. Neven,P. A. Fasching,S. Chia,G. Jerusalem,M. De Laurentiis,S.-A. Im,K. Petrakova,G. V. Bianchi,M. Martín,A. Nusch,G. S. Sonke,L. De la Cruz-Merino,

Breast cancer research : BCRno. 1 (2023): 1-10

引用3浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn